Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells 83,219 Shares of Stock

Key Points

• Dyne Therapeutics director Jason Rhodes sold 83,219 shares on May 6 at an average price of $18.18 for about $1.51 million, cutting his holding by 91.27% to 7,962 shares; the sale was executed under a pre‑arranged Rule 10b5‑1 plan.
• DYN traded at $18.84 mid‑day with a $3.11 billion market cap, a one‑year range of $8.06–$25.00, 50‑ and 200‑day moving averages near $17.94 and $18.56, and a negative PE of -5.32.
• Analyst sentiment is mixed but averages to a "Moderate Buy" with a $35.14 consensus target, while individual price targets and ratings vary widely, including recent downgrades and buy reaffirmations.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 83,219 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the completion of the transaction, the director owned 7,962 shares of the company's stock, valued at $144,749.16. This represents a 91.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

NASDAQ:DYN traded up $1.37 during mid-day trading on Wednesday, hitting $18.84. 1,720,199 shares of the company's stock traded hands, compared to its average volume of 2,090,953. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25. The firm's 50 day simple moving average is $17.94 and its 200 day simple moving average is $18.56. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00. The company has a market cap of $3.11 billion, a PE ratio of -5.32 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.02). Sell-side analysts expect that Dyne Therapeutics, Inc. will post -2.94 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors have recently bought and sold shares of the stock. Hilton Head Capital Partners LLC purchased a new stake in Dyne Therapeutics in the first quarter valued at approximately $26,000. Chung Wu Investment Group LLC purchased a new stake in Dyne Therapeutics in the third quarter valued at approximately $30,000. Strs Ohio purchased a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Dyne Therapeutics by 25.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company's stock valued at $70,000 after purchasing an additional 1,109 shares during the period. Finally, Aster Capital Management DIFC Ltd purchased a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $84,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DYN shares. Wall Street Zen downgraded shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday. Morgan Stanley decreased their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an "overweight" rating on the stock in a research note on Monday, March 2nd. Chardan Capital reaffirmed a "buy" rating and set a $38.00 price target on shares of Dyne Therapeutics in a research note on Monday, March 9th. HC Wainwright decreased their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, March 3rd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Dyne Therapeutics from $17.00 to $16.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 20th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $35.14.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.